Because combination therapy options are typically used to treat cancer, managed care professionals explore the high costs of newer treatment options for the treatment of cancer and raise questions about how the costs of drugs are determined. The discussion leads into a debate about whether high costs of combination therapies will underestimate their benefits and deter patients from receiving such necessary therapy.
Daniel J. George, MD, explains that different combination regimens have different dosage requirements. Combinations with ipilimumab require a different dosage regimen than immunotherapy, which impacts decisions on how to allocate financial resources.
Dr George continues by explaining that when looking at the cost-benefit ratio for a combination therapy, the cost should be determined based on the life span of the patient and should include all subsequent therapies.
Jeffrey Weber, MD, PhD, questions whether combination therapies currently in developmental stages, such as PD1 and Ipi, will be affordable to patients due to their high costs.
Because there is no clear answer to whether or not a patient will be able to afford a therapy option, Michael Kolodziej, MD, concludes that oncologists will need to base treatment decisions on the overall value of a treatment’s benefits. If a patient will be treated with a combination therapy, the treatment should be used in a setting where the patient has the potential for long-term survival.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More